Randomised clinical trial: Twice daily esomeprazole 40 mg vs. pantoprazole 40 mg in Barrett's oesophagus for 1 year

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 9, 2011, Pages 1019-1027

  De Bortoli, N ^a   Martinucci, I ^a   Piaggi, P ^a   Maltinti, S ^a   Bianchi, G ^b   Ciancia, E ^b   Gambaccini, D ^a   Lenzi, F ^a   Costa, F ^a   Leonardi, G ^a   Ricchiuti, A ^a   Mumolo, M G ^a   Bellini, M ^a   Blandizzi, C ^a   Marchi, S ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; ESOMEPRAZOLE; KI 67 ANTIGEN; PANTOPRAZOLE;

ADULT; AGED; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOSCOPY; ESOPHAGUS BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STOMACH ACID; TREATMENT DURATION; TREATMENT RESPONSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; APOPTOSIS; BARRETT ESOPHAGUS; CELL PROLIFERATION; CYCLOOXYGENASE 2 INHIBITORS; ESOPHAGEAL PH MONITORING; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953689337     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04616.x     Document Type: Article

References (43)

1. Winters C Jr, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987; 92: 118-24. (Pubitemid 17207669)
2. Csendes A, Smok G, Burdiles P, et al. Prevalence of intestinal metaplasia according to the length of the specialized columnar epithelium lining the distal esophagus in patients with gastroesophageal reflux. Dis Esophagus 2003; 16: 24-8. (Pubitemid 36603490)
3. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR,. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-3. (Pubitemid 23033424)
4. Cameron AJ, Lomboy CT, Pera M, Carpenter HA,. Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. Gastroenterology 1995; 109: 1541-6.
5. Falk GW,. Barrett's esophagus. Gastroenterology 2002; 122: 1569-91. (Pubitemid 34533554)
6. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984; 87: 927-33. (Pubitemid 14040468)
7. Cameron AJ, Ott BJ, Payne WS,. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. N Engl J Med 1985; 313: 857-9. (Pubitemid 15250200)
8. Gerson LB, Shetler K, Triadafilopoulos G,. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett's oesophagus. Dig Liver Dis 2005; 37: 651-8. (Pubitemid 44356081)
9. Ouatu-Lascar R, Triadafilopoulos G,. Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. Am J Gastroenterol 1998; 93: 711-6. (Pubitemid 29063908)
10. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE,. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 2004; 99: 1877-83. (Pubitemid 39421227)
11. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC,. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180: 387-91. (Pubitemid 38528957)
12. Fitzgerald RC, Omary MB, Triadafilopoulos G,. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98: 2120-8. (Pubitemid 26376301)
13. Souza RF, Shewmake K, Terada LS, Spechler SJ,. Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 2002; 122: 299-307. (Pubitemid 34126346)
14. Morgan C, Alazawi W, Sirieix P, Freeman T, Coleman N, Fitzgerald R,. In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line. Am J Gastroenterol 2004; 99: 218-24. (Pubitemid 38279860)
15. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80. (Pubitemid 29333764)
16. Sampliner RE,. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 1028-32.
17. Kahrilas PJ, Quigley EM,. Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996; 110: 1982-96.
18. Weusten BL, Roelofs JM, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ,. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994; 107: 1741-5. (Pubitemid 24357628)
19. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30. (Pubitemid 38962298)
20. Sharma P, Sampliner RE, Camargo E,. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997; 92: 582-5. (Pubitemid 27184368)
21. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996; 44: 700-5. (Pubitemid 26428331)
22. Gerson LB, Boparai V, Ullah N, Triadafilopoulos G,. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors. Aliment Pharmacol Ther 2004; 20: 637-43. (Pubitemid 39279052)
23. Fitzgerald RC, Omary MB, Triadafilopoulos G,. Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's esophagus. Am J Physiol 1998; 275: G47-55.
24. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE,. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001; 96: 990-6. (Pubitemid 32319127)
25. Reid BJ, Sanchez CA, Blount PL, Levine DS,. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105: 119-29. (Pubitemid 23234027)
26. Szachnowicz S, Cecconello I, Iriya K, Marson AG, Takeda FR, Gama-Rodrigues JJ,. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background. Clinics (Sao Paulo) 2005; 60: 103-12.
27. Halm U, Tannapfel A, Breitung B, Breidert M, Wittekind CW, Mossner J,. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Hepatogastroenterology 2000; 47: 962-6.
28. Yamauchi T, Watanabe M, Kubota T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis Colon Rectum 2002; 45: 98-103. (Pubitemid 34072758)
29. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK,. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-9. (Pubitemid 24007679)
30. Kromer W, Horbach S, Luhmann R,. Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology 1999; 59: 57-77. (Pubitemid 29355819)
31. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G,. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999; 117: 327-35. (Pubitemid 29352940)
32. Saccar CL,. The pharmacology of esomeprazole and its role in gastric acid related diseases. Expert Opin Drug Metab Toxicol 2009; 5: 1113-24.
33. Vachhani R, Olds G, Velanovich V,. Esomeprazole: a proton pump inhibitor. Expert Rev Gastroenterol Hepatol 2009; 3: 15-27.
34. Miner P Jr, Katz PO, Chen Y, Sostek M,. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20. (Pubitemid 38020098)
35. Wilder-Smith C, Backlund A, Eckerwall G, Lind T, Fjellman M, Rohss K,. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study. Clin Drug Investig 2008; 28: 333-43. (Pubitemid 351685390)
36. Wetscher GJ, Schwelberger H, Unger A, et al. Reflux-induced apoptosis of the esophageal mucosa is inhibited in Barrett's epithelium. Am J Surg 1998; 176: 569-73. (Pubitemid 29056652)
37. Chen LQ, Hu CY, Der Sarkissian S, et al. Apoptosis in Barrett's oesophagus following antireflux surgery. Br J Surg 2002; 89: 1444-9.
38. Umansky M, Yasui W, Hallak A, et al. Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 2001; 20: 7987-91. (Pubitemid 34001559)
39. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M,. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62: 1503-38. (Pubitemid 34804157)
40. Chong E, Ensom MH,. Pharmacogenetics of the proton pump inhibitors: a systematic review. Pharmacotherapy 2003; 23: 460-71. (Pubitemid 36384325)
41. Tonini M, Vigneri S, Savarino V, Scarpignato C,. Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Dig Liver Dis 2001; 33: 600-6. (Pubitemid 32998272)
42. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997; 62: 619-28. (Pubitemid 28068065)
43. Coenraad M, Masclee AA, Straathof JW, Ganesh S, Griffioen G, Lamers CB,. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis? Am J Gastroenterol 1998; 93: 1068-72. (Pubitemid 29080952)